Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SOLARA.NS
Strong BuyPremium GrowerSolara Active Pharma Sciences Limited · Healthcare · India · $357M · Avg Vol: $4M/d
81
StockRankGet insider-trade alerts
Q
51
V
39
M
87
P/E (TTM)
—
ROE
-0.6%
D/E
0.5x
Dividend %
—
COMPANY DESCRIPTION
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 13.8B | 12.4B | 12.4B | 13.3B | -1.2% | 14.3B |
| EPS (INR) | -5.68 | -148.51 | 0.14 | -1.68 | — | -0.63 |
| Shares | 39.1M | 39.1M | 48.1M | 48.2M | +23.3% | 48.1M |
| Debt | 10.1B | 10.1B | 8.0B | 6.9B | -12.2% | 6.9B |
| Equity | 15.0B | 9.3B | 10.9B | 12.5B | -5.8% | — |
| Op CF | 1.6B | 1.1B | 2.1B | 1.5B | -0.7% | 1.5B |
| Inv CF | -811.4M | -35.1M | -368.3M | -988.3M | — | — |
| Fin CF | -1.1B | -1.1B | -1.8B | -535.5M | — | — |
Loading 1Y...
PRICE (1Y)+35.9%
SMA 50SMA 200
Close
$7.26
RSI (14)
64.0
52W High
$7.56
From 52W High
1.0%
SCORE BREAKDOWN
Quality
51
ROIC
6.3%59.4
ROE
-0.6%43.8
GP/Assets
29.9%63.3
Op. Margin
9.2%60.8
FCF/Assets
4.3%67.0
Piotroski
549.3
Int. Cover
1.0x38.8
D/E Ratio
0.55x27.2
Current Ratio
0.96x10.3
Value
39
P/E (TTM)
—N/A
EV/EBITDA
20.5x33.4
P/FCF
33.9x43.0
P/B
2.4x55.1
P/S
2.3x63.9
Div Yield
—N/A
Momentum
87
52W High %
96%95.4
RS 6M
57%92.5
SMA 50/200
1.07x70.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
55%75.4
FUNDAMENTALS
Market Cap
$357M
P/E (Forward)
22.0x
Gross Margin
48.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SOLARA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SOLARA.NS | Solara Active Pharma Sciences Limited(you) | $357M | 81 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 71 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%